A Study Comparing Chemotherapy to CPX-351 and/or Gilteritinib for Acute Myeloid Leukemia
Phase 3
1,186
about 8.9 years
≤21
185 sites in AL, AR, AZ +44
What this study is about
Researchers are testing whether a treatment with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib, in addition to standard chemotherapy, improves outcomes for people newly diagnosed with acute myeloid leukemia. The trial will compare the effects of this new treatment approach to standard chemotherapy alone.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Fludeoxyglucose F-18
- 2.Questionnaire Administration
- 3.Take Asparaginase Erwinia chrysanthemi
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS, cytarabine, Antineoplastic Agent [TC] (DNA Polymerase Inhibitors), Cardiovascular Agent [TC] (Chelating Activity), etoposide, fludeoxyglucose (18F), gemtuzumab ozogamicin, Antineoplastic Agent [TC] (Receptor Tyrosine Kinase Inhibitors)
injection (Injection), infusion, injection, intravenous, oral (Oral Tablet)
Primary: Event-free survival (EFS)
Secondary: Incidence of adverse events, Overall survival (OS)
diagnostic, biopsy, imaging
Oncology